Fleurir ABX LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Pristinamycin Compositions, LpxC compositions, Their Improvements, and Combinations Thereof (US 10,307,457) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Combination Therapy Effective Against Microorganisms, Including Drug Resistant Microorganisms (US 11,925,653) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Pristinamycin Compositions, LpxC Compositions, Their Improvements, and Combinations Thereof (US 11,951,148) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,539,305 | Pristinamycin Compositions, LPXC Compositions, Their Improvements, and Combinations Thereof In force · High confidence | In force | High confidence | |
| US 9,872,884 | Pristinamycin Compositions, LPXC Compositions, Their Improvements, and Combinations Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,307,457 | Pristinamycin Compositions, LpxC compositions, Their Improvements, and Combinations Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,951,148 | Pristinamycin Compositions, LpxC Compositions, Their Improvements, and Combinations Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,141,453 | Pristinamycin Compositions, LpxC Compositions, Their Improvements, and Combinations Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,898,501 | Combination Therapy Effective Against Microorganisms, Including Drug Resistant Microorganisms In force · High confidence | In force | High confidence | |
| US 11,925,653 | Combination Therapy Effective Against Microorganisms, Including Drug Resistant Microorganisms In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending